View in EDS HTML Full Text PDF Full Text

Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.

Saved in:
Bibliographic Details
Title: Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
Authors: Eron JJ; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA., Cook PP; Division of Infectious Diseases, East Carolina University, Greenville, North Carolina, USA., Mehrotra ML; Cinical Research, Gilead Sciences, Inc, Foster City, California, USA., Huang H; Biostatistics, Gilead Sciences, Inc, Foster City, California, USA., Caskey M; Laboratory of Molecular Immunology, Rockefeller University, New York, New York, USA., Crofoot GE; Crofoot MD Clinic and Research Center, Houston, Texas, USA., Gorgos L; AXCES Research Group, Santa Fe, New Mexico, USA., VanderVeen LA; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA., Zheng Y; Clinical Pharmacology, Gilead Sciences, Inc, Foster City, California, USA., Collins SE; Clinical Development, Gilead Sciences, Inc, Foster City, California, USA., Osiyemi OO; Triple O Research Institute PA, West Palm Beach, Florida, USA., Brinson C; Central Texas Clinical Research, Austin, Texas, USA., DeJesus E; Orlando Immunology Center, Orlando, Florida, USA.
Source: The Journal of infectious diseases [J Infect Dis] 2025 Jul 11; Vol. 231 (6), pp. 1440-1444.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40176256
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Eron+JJ%22">Eron JJ</searchLink>; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Cook+PP%22">Cook PP</searchLink>; Division of Infectious Diseases, East Carolina University, Greenville, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Mehrotra+ML%22">Mehrotra ML</searchLink>; Cinical Research, Gilead Sciences, Inc, Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Huang+H%22">Huang H</searchLink>; Biostatistics, Gilead Sciences, Inc, Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Caskey+M%22">Caskey M</searchLink>; Laboratory of Molecular Immunology, Rockefeller University, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Crofoot+GE%22">Crofoot GE</searchLink>; Crofoot MD Clinic and Research Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Gorgos+L%22">Gorgos L</searchLink>; AXCES Research Group, Santa Fe, New Mexico, USA.<br /><searchLink fieldCode="AU" term="%22VanderVeen+LA%22">VanderVeen LA</searchLink>; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Zheng+Y%22">Zheng Y</searchLink>; Clinical Pharmacology, Gilead Sciences, Inc, Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Collins+SE%22">Collins SE</searchLink>; Clinical Development, Gilead Sciences, Inc, Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Osiyemi+OO%22">Osiyemi OO</searchLink>; Triple O Research Institute PA, West Palm Beach, Florida, USA.<br /><searchLink fieldCode="AU" term="%22Brinson+C%22">Brinson C</searchLink>; Central Texas Clinical Research, Austin, Texas, USA.<br /><searchLink fieldCode="AU" term="%22DeJesus+E%22">DeJesus E</searchLink>; Orlando Immunology Center, Orlando, Florida, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220413675%22">The Journal of infectious diseases</searchLink> [J Infect Dis] 2025 Jul 11; Vol. 231 (6), pp. 1440-1444.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0413675 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6613 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200221899%22">00221899 </searchLink><i>NLM ISO Abbreviation: </i>J Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40176256
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/infdis/jiaf159
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1440
    Titles:
      – TitleFull: Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Eron JJ
      – PersonEntity:
          Name:
            NameFull: Cook PP
      – PersonEntity:
          Name:
            NameFull: Mehrotra ML
      – PersonEntity:
          Name:
            NameFull: Huang H
      – PersonEntity:
          Name:
            NameFull: Caskey M
      – PersonEntity:
          Name:
            NameFull: Crofoot GE
      – PersonEntity:
          Name:
            NameFull: Gorgos L
      – PersonEntity:
          Name:
            NameFull: VanderVeen LA
      – PersonEntity:
          Name:
            NameFull: Zheng Y
      – PersonEntity:
          Name:
            NameFull: Collins SE
      – PersonEntity:
          Name:
            NameFull: Osiyemi OO
      – PersonEntity:
          Name:
            NameFull: Brinson C
      – PersonEntity:
          Name:
            NameFull: DeJesus E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 07
              Text: 2025 Jul 11
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1537-6613
          Numbering:
            – Type: volume
              Value: 231
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: The Journal of infectious diseases
              Type: main
ResultId 1